Bridgeway Capital Management Inc. Sells 25,000 Shares of Selecta Biosciences Inc (SELB)
Bridgeway Capital Management Inc. lessened its stake in shares of Selecta Biosciences Inc (NASDAQ:SELB) by 33.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 50,000 shares of the company’s stock after selling 25,000 shares during the period. Bridgeway Capital Management Inc. owned 0.22% of Selecta Biosciences worth $778,000 at the end of the most recent reporting period.
A number of other institutional investors also recently bought and sold shares of the business. Rhumbline Advisers increased its stake in Selecta Biosciences by 43.7% during the 2nd quarter. Rhumbline Advisers now owns 16,792 shares of the company’s stock worth $222,000 after acquiring an additional 5,103 shares during the period. Schwab Charles Investment Management Inc. increased its stake in Selecta Biosciences by 37.0% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 33,700 shares of the company’s stock worth $447,000 after acquiring an additional 9,100 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Selecta Biosciences by 27.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 47,273 shares of the company’s stock valued at $626,000 after purchasing an additional 10,114 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Selecta Biosciences by 1.5% in the 3rd quarter. BlackRock Inc. now owns 897,480 shares of the company’s stock valued at $13,956,000 after purchasing an additional 12,916 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Selecta Biosciences by 11.9% in the 2nd quarter. Northern Trust Corp now owns 156,708 shares of the company’s stock valued at $2,076,000 after purchasing an additional 16,615 shares in the last quarter. Hedge funds and other institutional investors own 51.04% of the company’s stock.
Shares of SELB stock opened at $5.37 on Friday. The firm has a market capitalization of $128.32 million, a price-to-earnings ratio of -1.68 and a beta of 1.00. Selecta Biosciences Inc has a fifty-two week low of $4.74 and a fifty-two week high of $16.55.
SELB has been the topic of a number of research analyst reports. BidaskClub downgraded Selecta Biosciences from a “buy” rating to a “hold” rating in a report on Friday, October 5th. Zacks Investment Research downgraded Selecta Biosciences from a “hold” rating to a “sell” rating in a report on Wednesday, August 29th. Janney Montgomery Scott reaffirmed a “buy” rating on shares of Selecta Biosciences in a report on Tuesday, October 23rd. Stifel Nicolaus reaffirmed a “buy” rating on shares of Selecta Biosciences in a report on Tuesday, October 23rd. Finally, Mizuho reaffirmed a “buy” rating and issued a $30.00 target price on shares of Selecta Biosciences in a report on Monday, November 5th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $23.21.
COPYRIGHT VIOLATION NOTICE: “Bridgeway Capital Management Inc. Sells 25,000 Shares of Selecta Biosciences Inc (SELB)” was first posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2018/12/08/bridgeway-capital-management-inc-sells-25000-shares-of-selecta-biosciences-inc-selb.html.
About Selecta Biosciences
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.
Featured Story: Asset Allocation Models, Which is Right For You?
Want to see what other hedge funds are holding SELB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Selecta Biosciences Inc (NASDAQ:SELB).
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.